Company release
Nanoform Finland Plc
June 13, 2022
18:00 Finnish time / 17:00 Swedish time
Nanoform Chief of Business Operations Gonçalo Andrade steps down
Helsinki, Finland – Dr. Gonçalo Andrade has decided to leave the role as Chief of Business Operations (CBO) at Nanoform to return to the private equity industry, at a newly started fund in Italy. He will continue in his Nanoform role until late August, securing a smooth transition of his responsibilities.
“I would like to thank all Nanoformers for our fantastic journey together and I’m looking forward as a shareholder to the continued success of Nanoform during the coming years“, said Dr. Gonçalo Andrade, Chief of Business Operations at Nanoform.
“We want to thank Gonçalo for his excellent work contribution during the last years. It has been a true pleasure to work with him and I wish him all the best in his future endeavors in the private equity industry”, said Prof. Edward Hæggström, Chief Executive Officer of Nanoform.
For further information, please contact:
Edward Hæggström, CEO
edward.hæggström@nanoform.com / +358 29 370 0150
For investor relations queries, please contact:
Henri von Haartman, Director of Investor Relations
hvh@nanoform.com / +46 7686 650 11
About Nanoform
Nanoform is an innovative nanoparticle medicine enabling company. Nanoform works together with pharma and biotech partners globally to provide hope for patients in developing new and improved medicines utilizing Nanoform’s platform technologies. The company focuses on reducing clinical attrition and on enhancing drug molecules’ performance through its nanoforming technologies and formulation services. Nanoform’s capabilities include GMP manufacturing, and its services span the small to large molecule development space with a focus on solving key issues in drug solubility and bioavailability and on enabling novel drug delivery applications. Nanoform’s shares are listed on the Premier-segment of Nasdaq First North Growth Market in Helsinki (ticker: NANOFH) and Stockholm (ticker: NANOFS). Certified Adviser: Danske Bank A/S, Finland Branch, +358 40 744 1900. For more information, please visit www.nanoform.com.
Forward-Looking Statements
This press release contains forward-looking statements, including, without limitation, statements regarding Nanoform’s strategy, business plans and focus. The words may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, any related to Nanoform’s business, operations, clinical trials, supply chain, strategy, goals and anticipated timelines, competition from other companies, and other risks described in the Report of the Board of Directors and Financial Statements for the year ended December 31, 2021 as well as our other past disclosures. Nanoform cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. Nanoform disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent Nanoform’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.